News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
百奧賽圖(02315.HK)合作夥伴NEOK Bio雙抗ADC NEOK002獲准美國臨床試驗
百奧賽圖－Ｂ(02315.HK)宣布，公司合作夥伴NEOK Bio, Inc.近日獲得美國食品藥品監督管理局對其在研新 藥NEOK002的新藥臨床試驗申請批准。NEOK002是一款靶向EGFR/ MUC1的抗體偶聯藥物(「ADC」)，擬用於實體瘤治療。NEOK Bio計劃於2026年第二季度啟動I期臨床試驗，並預計於2027年公佈初步臨床數據。(hc/w)~...
Reset
Send
The window will close in 5 seconds
百奧賽圖(02315.HK)合作夥伴NEOK Bio雙抗ADC NEOK002獲准美國臨床試驗
Close
Recommend
1
Positive
3
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

百奧賽圖－Ｂ(02315.HK)  -2.700 (-4.515%)    Short selling $979.53K; Ratio 1.703%   宣布，公司合作夥伴NEOK Bio, Inc.近日獲得美國食品藥品監督管理局對其在研新 藥NEOK002的新藥臨床試驗申請批准。NEOK002是一款靶向EGFR/ MUC1的抗體偶聯藥物(「ADC」)，擬用於實體瘤治療。

NEOK Bio計劃於2026年第二季度啟動I期臨床試驗，並預計於2027年公佈初步臨床數據。(hc/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-21 16:25.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.